Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly liposomal doxorubicin and cisplatin in epithelial ovarian cancer (phase I)
jRCTs031200007Phase 1Completed
- Start
- Jun 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doxorubicin and cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC). Primary endpoint: Dose-limiting toxicity frequency. Started Jun 2020; status: completed.
02
Drugs
doxorubicincisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCTs031200007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200007.